Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting.
Leticia LeonMarina PeñuelasFrancisco Javier CandelDalifer FreitesLuis Rodriguez-RodriguezBenjamín Fernández GutiérrezJuan Angel JoverLydia AbasoloPublished in: Therapeutic advances in musculoskeletal disease (2019)
The incidence of IOIb due to bDMARDs was 23 cases per 1000 patient-years. Close monitoring should be taken in the RA patients treated with bDMARDs and glucocorticosteroids, mainly in elderly patients and those with a low total lymphocyte count at the beginning of bDMARD treatment.